+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Saudi Pharmaceuticals Market Development Analysis

  • ID: 2904206
  • Report
  • Region: Saudi Arabia
  • 110 Pages
  • Kuick Research
1 of 3


  • Astra
  • GSK
  • Jamjoom Pharma
  • Novartis
  • Pfizer
  • MORE
The Saudi Arabia Pharmaceutical market has recorded significant growth over the years driven by various factors like increasing ageing population mostly in the above 60 years bracket, changing demographics and rise in the incidence of lifestyle diseases, increased spending power, result driven government initiatives to promote the growth of indigenous pharmaceutical companies. Inspite of the progress, the pharmaceutical sector in the Saudi Arabia is still in an emerging phase, and drug manufacturing is at a relatively nascent stage owing to many challenges, which need to be resolved. The Saudi pharmaceuticals market has accounted for more than to 50% of all pharmaceutical products sales in the GCC region.
Saudi Arabia relies substantially on imports of pharmaceutical products, primarily from Europe, to meet local demand as a result of insufficient domestic drug production and lack of indigenous research capabilities. Government is taking efforts to promote FDI in the pharmaceutical sector especially directed to help development of skills of local companies to manufacture patented medicines as well. Policies like free trade agreements have played a significant role in encouraging foreign investments. Increased penetration of the healthcare sector by insurance providers, price regulation guidelines to ensure uniformity in pricing and dedicated healthcare reforms, have further ensured growth of pharmaceutical market in recent years.

Saudi Arabia is expected to emerge as one of the fastest growing markets in future. The country is one of the most developed and technologically advanced medical sectors in the GCC Region with modern equipment and amenities. Pharmaceuticals products sales in Saudi Arabia are expected to surpass US$ 7 Billion by 2018 as compare to US$ 4.40 Billion 2013.

Saudi Arabia Pharmaceutical Market Development Analysis Report Highlight:
- Market Overview
- Drug Pricing system
- Disease Prevalence
- Market by segment: Generics, Branded & OTC
- Favorable Market Dynamics
- Regulatory Framework
- Key Regulatory Enforcement Departments

Note: Product cover images may vary from those shown
2 of 3


  • Astra
  • GSK
  • Jamjoom Pharma
  • Novartis
  • Pfizer
  • MORE
1. Saudi Arabia Pharmaceutical Market Overview
1.1 Current Market Scenario
1.2 Disease Prevalence

2. Pharmaceutical Market by Segment
2.1 Branded Drugs
2.2 Generic drugs
2.3 OTC

3. Saudi Arabia Drug Pricing System

4. Saudi Arabia Pharmaceutical Market Dynamics
4.1 Market Dominance in Middle East
4.2 Support to Domestic Pharmaceutical Industry
4.3 Favorable & Established Regulatory Framework
4.4 Preference for OTC & Generics Drugs
4.5 Import Dependent Market
4.6 Challenges to be Resolved

5. Saudi Arabia Pharmaceutical Market Future Outlook

6. Key Regulatory Enforcement Departments
6.1 National Drug and Poison Information Center
6.2 National Pharmacovigilance Center
6.3 Licensing Directorate
6.4 Executive Directorate of Laboratories
6.5 Executive Directorate of Inspection and Law Enforcement
6.6 Executive Directorate of Product Evaluation & Standard Setting

7. Pharmaceutical Market Regulatory Framework
7.1 Drug Approval Process (Generics, Biologicals, Radipharmaceuticals & New Chemical Entity)
7.2 Monoclonal Antibodies and Related Products Quality Guideline
7.3 Law of Pharmaceutical Establishments and Preparations
7.4 Guidelines on Biosimilars
7.4.1 Insulin
7.4.2 Interferons
7.4.3 Erythropoietin
7.4.4 Granulocyte-Colony Stimulating Factor
7.4.5 Human Growth Hormone
7.5 Priority Review of Product Registration
7.6 Drug Barcoding Specifications

8. Competitive Landscape
8.2 Tabuk Pharmaceuticals
8.3 Jamjoom Pharma
8.4 Julphar (Gulf Pharmaceutical Industries)
8.5 GSK
8.6 Pfizer
8.7 Novartis
8.8 Astra

List Of Tables and Figures:

Table 3-1: Pricing History and Legal Background in Saudi Arabia
Table 3-2: Drug Pricing for Generics
Table 3-3: Drug Pricing for Fixed Combinations

Figure 1-1: Saudi Arabia Pharmaceutical Market (US$ Billion), 2013-2018
Figure 1-2: Saudi Arabia Pharmaceutical Market by Segment (US$ Billion), 2013-2018
Figure 1-3: Saudi Arabia Pharmaceutical Market by Segment (%), 2013 & 2018
Figure 1-4: Factors Driving Growth in Saudi Pharmaceuticals Market
Figure 1-5: Burden of Communicable & Non Communicable Diseases in Saudi Arabia, 2012 & 2030
Figure 1-6: Leading Causes of Death in Saudi Arabia, 2011

Figure 2-1: Saudi Arabian Branded Drugs Market Value (US$ Billion), 2013-2018
Figure 2-2: Saudi Arabian Generics Drug Market Value (US$ Billion), 2013-2018
Figure 2-3: Saudi Arabian OTC Drug Market (US$ Billion), 2013-2018

Figure 3-1: Components of Drug Pricing System in Saudi Arabia

Figure 4-1: Share of Saudi Arabia in GCC Pharmaceuticals Market, 2013
Figure 4-2: Government Healthcare Expenditure (US$ Billion), 2012 & 2013

Figure 7-1: Saudi Arabia Drug Approval Process
Figure 7-2: Process for Designating A Drug For The Priority Review
Figure 7-3: Drug Barcoding Standard
Figure 7-4: Drug Barcoding Sample


Note: Product cover images may vary from those shown
3 of 3


4 of 3
- Astra
- Jamjoom Pharma
- Julphar (Gulf Pharmaceutical Industries)
- Novartis
- Pfizer
- Tabuk Pharmaceuticals
Note: Product cover images may vary from those shown